Subcutaneous xenograft of the mel Rac human pigmentless melanoma cell line with NRAS mutation for preclinical study of anticancer targeted agents

摘要

FIELD: biotechnology; medicine.SUBSTANCE: invention relates to use of the subdermal xenografts of cell line of amelanotic human skin melanoma mel Rac with mutation NRAS gene and with adaptation to growth with stable kinetics in immunodeficient Balb/c nude mice for preclinical study of antineoplastic targeted agents.EFFECT: present invention makes it possible to expand the range of xenografts for preclinical study of antineoplastic targeted agents.1 cl, 4 dwg, 4 tbl